Shots:

• Novartis to receive upfront from Sumitomo. Sumitomo to get rights to co-promote Novartis’ Equa and EquMet from July’19 in addition to distribution rights from Nov’19- receiving payment for promotion & commercialization in Japan
• The focus of the collaboration is to expand Sumitomo’s diabetes portfolio in Japan and is expected to generate annual revenue of ~$1.8M
• Equa (50mg) is an oral DPP-4 inhibitor- inhibiting glucagon secretion by increasing the conc. of GLP-1. EquMet is a combination of DPP-4 inhibitor and biguanide- effectively lowers blood sugar level by stimulating insulin secretion & improving insulin resistance

Ref: Sumitomo Dainippon Pharma | Image: The Hindu Business Line